Is MS treatment effective long-term?

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

Bernd Merkel, Helmut Butzkueven, Anthony L Traboulsee, Eva Havrdova, Tomas Kalincik

2017-06-01

BACKGROUND: Immunotherapy initiated early after first presentation of relapsing-remitting multiple sclerosis is associated with im..

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Tomas Kalincik, J William L Brown, Neil Robertson, Mark Willis, Neil Scolding, Claire M Rice, Alastair Wilkins, Owen Pearson, Tjalf Ziemssen, Michael Hutchinson, Christopher McGuigan, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard

2017-04-01

BACKGROUND: Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relap..

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

Nathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, Jeannette Lechner-Scott, Mark Slee, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Pierre Duquette, Marc Girard, Alexandre Prat, Pierre Grammond, Raymond Hupperts, Francois Grand'Maison, Patrizia Sola, Eugenio Pucci, Roberto Bergamaschi, Celia Oreja-Guevara, Vincent Van Pesch

2017-03-01

OBJECTIVE: To evaluate variability and predictability of disability trajectories in moderately advanced and advanced multiple scle..

Defining secondary progressive multiple sclerosis

Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, Tim Spelman, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Marc Girard, Pierre Duquette, Alexandre Prat, Alessandra Lugaresi, Francois Grand'Maison, Pierre Grammond, Raymond Hupperts, Raed Alroughani, Patrizia Sola, Cavit Boz, Eugenio Pucci, Jeanette Lechner-Scott

2016-09-01

Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis

Vilija G Jokubaitis, Tim Spelman, Tomas Kalincik, Johannes Lorscheider, Eva Havrdova, Dana Horakova, Pierre Duquette, Marc Girard, Alexandre Prat, Guillermo Izquierdo, Pierre Grammond, Vincent Van Pesch, Eugenio Pucci, Francois Grand'Maison, Raymond Hupperts, Franco Granella, Patrizia Sola, Roberto Bergamaschi, Gerardo Iuliano, Daniele Spitaleri

2016-07-01

OBJECTIVE: To identify predictors of 10-year Expanded Disability Status Scale (EDSS) change after treatment initiation in patients..

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Tim Spelman, Orla Gray, Robyn Lucas, Helmut Butzkueven

2015-12-01

This report describes a novel Stata-based application of trigonometric regression modelling to 55 years of multiple sclerosis rela..

Predictors of disability worsening in clinically isolated syndrome

Vilija G Jokubaitis, Tim Spelman, Tomas Kalincik, Guillermo Izquierdo, Francois Grand'Maison, Pierre Duquette, Marc Girard, Alessandra Lugaresi, Pierre Grammond, Raymond Hupperts, Jose Cabrera-Gomez, Celia Oreja-Guevara, Cavit Boz, Giorgio Giuliani, Ricardo Fernandez-Bolanos, Gerardo Iuliano, Jeannette Lechner-Scott, Freek Verheul, Vincent van Pesch, Tatjana Petkovska-Boskova

2015-05-01

OBJECTIVE: To assess demographic, clinical, magnetic resonance imaging, and treatment exposure predictors of time to 3 or 12-month..

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

Anna He, Tim Spelman, Vilija Jokubaitis, Eva Havrdova, Dana Horakova, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Marc Girard, Eugenio Pucci, Gerardo Iuliano, Raed Alroughani, Celia Oreja-Guevara, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Patrizia Sola, Daniele Spitaleri, Franco Granella

2015-04-01

IMPORTANCE: After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicia..

Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Tomas Kalincik, Dana Horakova, Tim Spelman, Vilija Jokubaitis, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Csilla Rozsa, Pierre Grammond, Raed Alroughani, Pierre Duquette, Marc Girard, Eugenio Pucci, Jeannette Lechner-Scott, Mark Slee, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Raymond Hupperts, Freek Verheul, Suzanne Hodgkinson

2015-03-01

OBJECTIVE: In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians..

Seasonal Variation of Relapse Rate in Multiple Sclerosis is Latitude Dependent

Tim Spelman, Orla Gray, Maria Trojano, Thor Petersen, Guillermo Izquierdo, Alessandra Lugaresi, Raymond Hupperts, Roberto Bergamaschi, Pierre Duquette, Pierre Grammond, Giorgio Giuliani, Cavit Boz, Freek Verheul, Celia Oreja-Guevara, Michael Barnett, Francois Grand'Maison, Maria Edite Rio, Jeannette Lechner-Scott, Vincent Van Pesch, Ricardo Fernandez Bolanos

2014-12-01

OBJECTIVE: Previous studies assessing seasonal variation of relapse onset in multiple sclerosis have had conflicting results. Smal..

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

Tomas Kalincik, Vino Vivek, Vilija Jokubaitis, Jeannette Lechner-Scott, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Francois Grand'Maison, Raymond Hupperts, Celia Oreja-Guevara, Roberto Bergamaschi, Gerardo Iuliano, Raed Alroughani, Vincent Van Pesch, Maria Pia Amato, Mark Slee, Freek Verheul, Ricardo Fernandez-Bolanos, Marcela Fiol, Daniele La Spitaleri

2013-12-01

The aim of this work was to evaluate sex differences in the incidence of multiple sclerosis relapses; assess the relationship betw..